Bicocca Open Archive

Logo unimib boa
PUOTI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.291
EU - Europa 3.930
AS - Asia 2.206
AF - Africa 22
SA - Sud America 11
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 4
Totale 13.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.172
SG - Singapore 1.155
RU - Federazione Russa 825
IT - Italia 778
IE - Irlanda 758
SE - Svezia 659
HK - Hong Kong 443
DE - Germania 396
CN - Cina 304
ID - Indonesia 143
GB - Regno Unito 138
CA - Canada 92
UA - Ucraina 85
AT - Austria 83
FI - Finlandia 67
VN - Vietnam 54
IN - India 38
NL - Olanda 34
FR - Francia 33
TR - Turchia 33
MX - Messico 26
CZ - Repubblica Ceca 17
ES - Italia 16
DK - Danimarca 11
JP - Giappone 11
IR - Iran 9
BE - Belgio 8
PL - Polonia 8
ET - Etiopia 7
MU - Mauritius 5
EG - Egitto 4
PH - Filippine 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
AU - Australia 3
BR - Brasile 3
CL - Cile 3
GR - Grecia 3
NZ - Nuova Zelanda 3
IL - Israele 2
KR - Corea 2
KZ - Kazakistan 2
NG - Nigeria 2
RO - Romania 2
UG - Uganda 2
AM - Armenia 1
BD - Bangladesh 1
BG - Bulgaria 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
CY - Cipro 1
EC - Ecuador 1
EE - Estonia 1
EU - Europa 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MD - Moldavia 1
MK - Macedonia 1
PE - Perù 1
PT - Portogallo 1
SI - Slovenia 1
TH - Thailandia 1
TW - Taiwan 1
ZA - Sudafrica 1
ZM - Zambia 1
Totale 13.470
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.080
Singapore 1.032
Dublin 750
Fairfield 591
Chandler 479
Hong Kong 443
Houston 396
New York 390
Woodbridge 383
Princeton 379
Frankfurt am Main 325
Ashburn 322
Santa Clara 314
Wilmington 281
Seattle 219
Cambridge 196
Altamura 191
Milan 187
Lawrence 186
Jakarta 143
Jacksonville 111
San Diego 106
Dearborn 103
Vienna 72
Shanghai 68
Andover 64
Dong Ket 45
Beijing 43
London 41
Nanjing 40
Rome 40
Toronto 35
Falls Church 30
Lachine 28
Helsinki 26
Hangzhou 24
Norwalk 22
Fremont 20
Guangzhou 20
Boardman 18
Cuauhtémoc 17
Los Angeles 15
Pune 15
Nuremberg 14
Lappeenranta 13
Florence 12
Olomouc 12
Chicago 11
Ottawa 11
Redmond 11
Shenyang 11
Tianjin 11
Turin 11
Dallas 10
Madrid 10
Washington 10
Hebei 9
Jinan 9
Kilburn 9
San Mateo 9
Brussels 8
Lissone 8
Tokyo 8
Mumbai 7
Amsterdam 6
Bergamo 6
Cologno Monzese 6
Desio 6
Hounslow 6
Hyderabad 6
Mountain View 6
Nanchang 6
Ancona 5
Brno 5
Carate Brianza 5
Como 5
Groningen 5
Leawood 5
Naples 5
Parma 5
Winnipeg 5
Bologna 4
Bolzano 4
Bovisio Masciago 4
Chengdu 4
Islington 4
Munich 4
Prescot 4
Trumbull 4
Umeå 4
Weimar 4
Zhengzhou 4
Aachen 3
Auburn Hills 3
Birmingham 3
Brugherio 3
Changsha 3
Chiswick 3
Clearwater 3
Fiumefreddo di Sicilia 3
Totale 9.665
Salva come PNG Salva come JPEG
Nome #
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 212
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 199
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: Results from the Icona Foundation study 197
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 191
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 174
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 173
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort 172
Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA) 169
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 166
Characteristics and Clinical Implications of Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection, Italy 163
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure 161
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 155
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 150
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study 150
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 150
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 149
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 147
Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients 138
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients 136
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 133
24 HOUR ARTERIAL DISTENSIBILITY IS RELATED WITH ABPM NON-DIPPING PATTERN IN HIVPOSITIVE PATIENTS 131
Successful pre- and posttransplant sofosbuvir-based anti-hepatitis C virus treatment in persons living with human immunodeficiency virus infection 130
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C 127
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 124
Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection 118
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 115
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 114
24-Hour Blood Pressure Monitoring Patterns in HIV-Positive Patients and its Relationship with Arterial Distensibility 113
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 113
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 111
Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy 111
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 110
Factors Influencing Depression Endpoints Research (FINDER): Baseline results of Italian patients with depression 109
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011 109
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 103
Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients 103
HIV-positive to HIV-positive liver transplantation: To be continued 102
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 100
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 100
Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience 99
COVID-19 in liver transplant candidates: Pretransplant and post-transplant outcomes - An ELITA/ELTR multicentre cohort study 96
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 93
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: A longitudinal study 92
An update on integrase inhibitors: New opportunities for a personalized therapy?: The NEXTaim Project 91
Trends in all-cause mortality of hospitalized patients due to SARS-CoV-2 infection from a monocentric cohort in Milan (Lombardy, Italy) 90
Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV 87
24-hours arterial distensibility is related with ABPM non-dipping pattern in HIV-positive patients 85
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C 85
Home-based COVID 19 management: A consensus document from Italian general medical practitioners and hospital consultants in the Lombardy region (Italy) 82
HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects from the ICONA Italian Cohort of HIV-Infected Patients 81
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 79
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 77
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 76
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 72
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 72
HEFFICON: HIV effectiveness Italian conference 71
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV 71
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: Results from the Italian EPOKA-MASTER cohort 71
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 71
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients 70
Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: Results from the EPOKA-MASTER cohort 68
Neurological manifestations in patients hospitalized with COVID-19: A retrospective analysis from a large cohort in Northern Italy 67
Single-center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients 66
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 65
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres 64
The use of molecular assays in the management of viral hepatitis 64
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 63
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 61
Management of infections pre- and post-liver transplantation: report of an AISF consensus conference 61
Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab 60
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 60
Risk factors and clinical characteristics associated with hospitalization for community-acquired bacterial pneumonia in HIV-positive patients according to the presence of liver cirrhosis 60
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 59
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 58
Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapy 58
Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients 57
Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress? 57
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry 57
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 56
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis 56
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients with Lymphoproliferative Disorders on BTKi 55
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study 55
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 54
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 54
Prophylaxis and treatment of hepatitis B in immunocompromised patients 54
Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation—a position paper 52
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials 52
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 52
EASL recommendations on treatment of hepatitis C: Final update of the series☆ 52
Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation 51
Letter: sustained virological response and liver healing 51
Real life experiences in HCV management in 2018 51
Sex differences in electrolyte imbalances caused by SARS-CoV-2: A cross-sectional study 51
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 51
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy 50
Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease 50
Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts 50
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 50
Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination 49
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 49
Totale 9.389
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.134
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.134
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020500 0 0 0 0 0 97 69 79 80 46 89 40
2020/20211.907 64 114 89 102 117 113 125 389 267 156 204 167
2021/20221.821 73 108 261 174 85 119 42 270 125 100 86 378
2022/20232.602 463 748 231 174 112 429 24 139 162 21 68 31
2023/20242.557 51 63 78 69 344 590 440 55 291 47 100 429
2024/20253.434 511 1.151 429 375 655 313 0 0 0 0 0 0
Totale 14.413